Literature DB >> 10603

Tardive dyskinesia and depressive illness.

K L Davis, P A Berger, L E Hollister.   

Abstract

Tardive dyskinesia has been regarded as a long-term complication of neuroleptic administration to patients with the diagnosis of schizophrenia. However, nine of the first fourteen patients evaluated for an investigation of tardive dyskinesia met diagnostic criteria for depression. Neuroleptics produce blockade of post-synaptic dopaminergic receptors. Tardive dyskinesia occurs when neuroleptics are discontinued, and is regarded as a manifestation of super-sensitive post-synaptic dopaminergic receptors. Tardive dyskinesia occurs when neuroleptics are discontinued, and is regarded as a manifestation of super-sensitive post-synaptic dopaminergic receptors. Chronically decreased neurotransmission in the synapse of a patient with depression may contribute to the development of a super-sensitive receptor and could explain the high proportion of patients with depression seen in this sample of patients with tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 10603

Source DB:  PubMed          Journal:  Psychopharmacol Commun        ISSN: 0098-616X


  6 in total

Review 1.  Tardive dyskinesia.

Authors:  T R Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-16

Review 2.  Exploring the multifaceted neuroprotective actions of Emblica officinalis (Amla): a review.

Authors:  Ibraheem Husain; Saima Zameer; Tushar Madaan; Akram Minhaj; Wasim Ahmad; Asif Iqubaal; Abuzer Ali; Abul Kalam Najmi
Journal:  Metab Brain Dis       Date:  2019-03-08       Impact factor: 3.584

3.  A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines.

Authors:  G S Zubenko; B M Cohen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  State-dependent tardive dyskinesia in manic-depressive illness.

Authors:  R W de Potter; P Linkowski; J Mendlewicz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-07       Impact factor: 10.154

5.  Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients.

Authors:  A G Robertson; R Berry; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  On the pathogenesis of abnormal involuntary movements in lithium-treated patients with major affective disorder.

Authors:  R Axelsson; A Nilsson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.